Pharmacokinetics of high dose etoposide (VP 16–213)
- 1 October 1986
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 22 (10), 1149-1155
- https://doi.org/10.1016/0277-5379(86)90315-9
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Remission of Brain Metastases from Small-Cell Lung Cancer After High-Dose ChemotherapyAnnals of Internal Medicine, 1984
- Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation studyEuropean Journal of Cancer and Clinical Oncology, 1984
- Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.Journal of Clinical Oncology, 1984
- Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detectionJournal of Pharmaceutical and Biomedical Analysis, 1983
- Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancerCancer Chemotherapy and Pharmacology, 1982
- Noncompartmental Determination of the Steady-State Volume of Distribution for Any Mode of AdministrationJournal of Pharmaceutical Sciences, 1982
- ETOPOSIDE: A NEW ANTI-CANCER AGENTThe Lancet, 1981
- Nonlinear regression on multiple-dose dataJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesEuropean Journal of Cancer (1965), 1975
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975